• editor.aipublications@gmail.com
  • Track Your Paper
  • Contact Us
  • ISSN: 2456-8015
NAAS Journal 2026

International Journal Of Medical, Pharmacy And Drug Research(IJMPD)

  1. Home
  2. IJMPD
  3. Vol-8,Issue-2, April - June 2024
  4. Cancer: A review

For Authors

ijmpd doi
Author Guidelines Peer Review Process Plagiarism Policy Publication Ethics and Publication Malpractice Statement Editorial Board Call for Papers Publication Process Topics of Interest Track Status of Paper

Issues

Current Archive

Downloads

Download Certificate Paper Format Copyright Form

Indexing and Abstracting

aipublications google scholar aipublications academia ijmpd jgate ijmpd slide share

Cancer: A review

Harsimran Singh , Rajesh Kumar , Ajeet Pal Singh , Meenakshi Malhotra , Ritu Rani , Amar Pal Singh


International Journal of Medical, Pharmacy and Drug Research(IJMPD), Vol-8,Issue-2, April - June 2024, Pages 61-68 ,

Download | Downloads : 26 | Total View : 1887

Article Info: Received: 03 Apr 2024; Received in revised form: 05 May 2024; Accepted: 15 May 2024; Available online: 21 May 2024

Share

Cancer remains one of the most formidable challenges in modern medicine, posing significant health burdens globally. In recent years, extensive research efforts have aimed at understanding the intricate mechanisms underlying cancer development, progression, and treatment. This review provides a comprehensive overview of the latest advancements in cancer research across various domains. The elucidation of genetic and molecular alterations driving oncogenesis has revolutionized our understanding of cancer biology. Key discoveries in genomics, transcriptomics, and proteomics have unveiled the heterogeneous nature of tumors, paving the way for personalized treatment approaches. Moreover, advancements in high-throughput sequencing technologies have facilitated the identification of novel cancer biomarkers with diagnostic, prognostic, and therapeutic implications. The tumor microenvironment (TME) has emerged as a critical determinant of cancer progression and therapy response. Research focusing on the dynamic interactions between cancer cells, immune cells, and stromal components within the TME has led to the development of immunotherapeutic strategies, including immune checkpoint inhibitors and adoptive cell therapies, which have demonstrated remarkable efficacy in various cancer types. In addition to targeted therapies and immunotherapies, the advent of precision medicine has transformed cancer treatment paradigms. Molecular profiling of tumors enables clinicians to match patients with specific targeted therapies, optimizing therapeutic outcomes while minimizing adverse effects. Furthermore, the integration of artificial intelligence and machine learning algorithms in cancer research has facilitated the prediction of treatment responses and identification of novel therapeutic targets.

Oncogenesis, Immunotherapy, Precision Medicine, Tumor Microenvironment (TME), Artificial Intelligence in Cancer Research

[1] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. PMID: 21376230.
[2] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122. PMID: 23539594.
[3] Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. PMID: 25858804
[4] DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008 Oct 15;68(20):8643-53. doi: 10.1158/0008-5472.CAN-07-6611. PMID: 18922906.
[5] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.
[6] Colditz GA, Sellers TA, Trapido E. Epidemiology - identifying the causes and preventability of cancer? Nat Rev Cancer. 2006 May;6(5):75-83.
[7] Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018 Jul;68(1):31-54.
[8] Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet. 2014 Feb 22;383(9916):549-57.
[9] Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011 Oct 21;11(10):726-34.
[10] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74.
[11] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
[12] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013 Dec;19(11):1423-37.
[13] Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nat Rev Cancer. 2003 May;3(4):243-52.
[14] Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue R, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017 May;14(12):749-62.
[15] Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013 Mar 15;19(5):1021-34.
[16] Kaur G, Dufour JM. Cell lines: valuable tools or useless artifacts. Spermatogenesis. 2012 Jul 1;2(1):1-5.
[17] Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol. 2016 Jan 6;56:85-102.
[18] Williams F, Jeanetta S, Lloyd L, Sheridan K. Access to cancer services for rural colorectal cancer patients. J Rural Health. 2008;24(4):390-9.
[19] Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014 Jun;11(6):312-8.
[20] Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017 Sep 21;168(4):707-723.
[21] Williams F, Jeanetta S, Lloyd L, Sheridan K. Access to cancer services for rural colorectal cancer patients. J Rural Health. 2008;24(4):390-9.

aipub drij aipub scribd internet archive research bib scilit indiana tynd rootindexing aipub pdfsr aipub cite factor aipub issuu aipub wikicfp aipub google aipub slideshare aipub reddit aipub digg aipub tumblr aipub plurk aipub yudu Active Search Results
© 2021 AI Publications | All Rights Reserved